General Pharmacology: The Vascular System 1998-01-01

Comparison of the effects of NS-21 and terodiline on the QTc interval in dogs.

T Natsukawa, T Matsuzaki, S Hayashi, Y Ukai, Y Yoshikuni, K Kimura

Index: Gen. Pharmacol. 30(1) , 137-42, (1998)

Full Text: HTML

Abstract

1. NS-21 [(+/-)-4-diethylamino-1,1-dimethylbut-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate], its active metabolite, RCC-36, and terodiline, are mixed anticholinergic-Ca2+ antagonistic drugs. Among them, terodiline has been shown to cause torsade de pointes, a serious polymorphic ventricular tachycardia. It remains unknown, however, whether NS-21 or its active metabolite, RCC-36, produces torsade de pointes. 2. In anesthetized dogs, terodiline (10 mg/kg i.v.) significantly prolonged the QTc interval by 6-8%, an effect thought to be associated with torsade de pointes. In contrast, neither NS-21 nor RCC-36 (10 mg/kg i.v.) prolonged the QTc interval; therefore NS-21 is unlikely to cause ventricular tachyarrhythmias, such as those associated with terodiline. 3. The effects of NS-21, RCC-36 and terodiline on the action potential were investigated in guinea pig papillary muscle. However, none of these drugs prolonged the duration of the action potential, although only terodiline caused the muscle preparation to lose its excitability.


Related Compounds

Related Articles:

Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline.

1999-09-01

[J. Pharmacol. Exp. Ther. 290(3) , 1417-26, (1999)]

CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.

2000-07-01

[Br. J. Clin. Pharmacol. 50(1) , 77-80, (2000)]

Inhibition of cardiac inward-rectifier K+ current by terodiline.

1999-07-01

[Eur. J. Pharmacol. 370(3) , 319-27, (1999)]

Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.

2001-01-01

[Xenobiotica 31(8-9) , 633-50, (2001)]

In vitro preclinical cardiac assessment of tolterodine and terodiline: multiple factors predict the clinical experience.

2006-11-01

[J. Cardiovasc. Pharmacol. 48(5) , 199-206, (2006)]

More Articles...